Inovio Pharmaceuticals Inc (INO) Stock Analysis
Verdict: WATCH (do not buy)
FDA approval of VOCERYQ unlocks commercial revenue, but severe cash burn of $88.9M creates immediate dilution risk without new capital.
Investment score: 46/100
Analysis as of
Is Inovio Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assigns a WATCH rating to Inovio Pharmaceuticals Inc (INO) at $1.7899. While FDA accelerated approval for VOCERYQ triggers a pivotal re-rating catalyst, severe cash burn of $88.9M per year against $44.27M in cash elevates dilution risk over the next 6 months.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Inovio Pharmaceuticals Inc opportunities and risks
What speaks for INO
- FDA Accelerated Approval for VOCERYQ (INO-3107) received on November 2, 2026
What speaks against INO
- Immediate Equity Dilution Risk to Fund Commercial Launch
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INO | n/a | 0.0x | n/a | 0.0% | 0.0% | -61.9% |
| PLX | 10.6x | 2.6x | 7.2x | 69.2% | 23.5% | 3.7% |
| ARTV | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -47.9% |
| PYXS | n/a | 9.7x | n/a | 99.8% | -803.8% | -63.4% |
| TRDA | n/a | 42.5x | n/a | -754.7% | -3537.7% | -67.5% |
| AKBA | n/a | 0.9x | n/a | 79.5% | -13.5% | 20.5% |
| Peer median | n/a | 2.6x | n/a | 69.2% | -13.5% | -47.9% |
Frequently asked questions about Inovio Pharmaceuticals Inc (INO)
Is INO stock a good investment?
The TradeMates model rates Inovio Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 46/100. The TradeMates model assigns a WATCH rating to Inovio Pharmaceuticals Inc (INO) at $1.7899. While FDA accelerated approval for VOCERYQ triggers a pivotal re-rating catalyst, severe cash burn of $88.9M per year against $44.27M in cash elevates dilution risk over the next 6 months. This is algorithmic model output, not personal investment advice.
Is INO stock a buy?
The TradeMates model verdict for INO is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.